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1. Introduction 
Pancreatic ductal adenocarcinoma( PDAC) cancer is one of the most aggressive human 
cancers, and the fifth most frequent cause of cancer-related mortality in Western society. 
Pancreatic cancer is well known for high metastatic potential, early local invasion and poor 
outcome. The overall 5-year survival rate is less than 5%, respectively 10-30% for R0 
resection (Huang et al., 2010). Less than 10% of newly diagnosed pancreatic cancers could be 
detected in early-stage (Takayama et al., 2010).  
Clinical research in the field of cancer biomarkers is essential in understanding the biology 
and the heterogeneity of cancer disease. The factors involved in early PDAC development 
remain unknown. The detection of pancreatic cancer at early stages, the prediction of the 
potential resectability, or response to therapy are the current major challenges in improving 
the clinical outcome of PDAC. Therefore, predictive markers of responsiveness to adjuvant 
therapy would allow patients selection to appropriate treatment (Duffy et al., 2007). The aim 
of the postoperative surveillance following curative surgery for PDAC is to detect 
recurrences or metastases as early as possible. 
Currently, there are only few studies that have identified cancer biomarkers with clinical 
significance.  
Molecular biological factors are important tools for early diagnosis, prognosis, not only for 
therapeutic strategy but also for novel and more efficient therapeutic agents’ identification. 
On the other hand a biomarker must be easily quantified, in order to minimize the 
invasiveness of therapeutically interventions. Recent finding in the molecular biology field 
of pancreatic cancer have assisted in translational research, giving hope for individualized 
therapy and better disease management. 
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2. Identification of new potential tumor tissue biomarkers 
Much effort goes into finding new accurate prognostic, diagnostic single or combined tumor 
biomarkers. Nowadays, the research in this field is focused not only on finding biomarkers 
that could discriminate between pathological pancreas conditions (disease related 
biomarkers), but also to evaluate the aggressiveness grade of PDAC and to determine the 
therapy response (drug related biomarkers). 
Presently, screening for pancreatic cancer is based on state-of-the-art imaging or even 
invasive diagnostic methods (Balasenthil et al., 2011). Serum and other body fluids, such as 
urine, pancreatic juice represents sources available by less invasive methods for biomarkers 
screening. 
Several techniques like immunohistochemistry, fluorescence and chromogenic in situ 
hybridization, expression profiling- performed by microarray or quantitative real-time 
reverse transcriptase-polymerase chain reaction (qRT-PCR), and mutation analysis are used 
in identification of new biomarkers. Among these techniques, immunohistochemical tests 
remain the most widely used in routine practice and, importantly, in the assessment of 
biomarkers in translational research. 
In a recent study, Wacher et. al investigated the expression level of an oncofetal protein, 
insulin-like growth factor II messenger ribonucleic acid-binding protein 3 (IMP3), which 
represent a marker for tumor aggressiveness in many different tumors (Wachter et al., 2011; 
Ozdemir et al., 2011). 
The investigation was conducted on tissue biopsies from PDAC, chronic sclerosing 
pancreatitis, PDAC metastases cases in order to determine IMP3 expression. For IMP3 
expression evaluation large tissue sections were used in the immunohistochemical analysis. 
The results obtained showed that PDAC were positive for IMP3 expression in a high 
percentage (88.4%) of cases, whereas normal or inflammatory pancreatic tissue was weakly 
positive (23.1%). A strong IMP3 expression was found in PDAC metastases (94.4%). The 
sensitivity and specificity of IMP3 expression test to discriminate between PDAC and 
chronic sclerosing pancreatitis using core needle biopsies were found to be 88.4% and 94.6%, 
respectively. The authors consider that IMP3 might be an easy to use and potentially new 
immunohistochemical marker for the diagnosis of PDAC in core needle biopsies (Asioli et 
al., 2010; Walter et al., 2009).  
Another prognostic biomarker in PDAC which characterize the tumor aggressiveness 
recently studied was vimentin. Vimentin protein is a marker of mesenchymal 
differentiation, being correlated especially with aggressive carcinomas. In a high percentage 
primary pancreatic adenocarcinomas contain neoplastic cells that express vimentin, and the 
presence of this protein was correlated with poor histological differentiation and predicts a 
shorter postsurgical survival (Li et al., 2009; Handra-Luca et al., 2011). 
Several technical strategies (SDS-PAGE, mass spectrometry, immunoblot) are used to find 
candidate biomarkers for the presurgical management of malignant and premalignant 
pancreatic conditions. Pancreatic cystic neoplasms represent 10−15% of primary cystic 
masses of the pancreas and are detected with an increasing frequency due to the use of 
advanced imaging modalities in clinical practice. On the other hand, the diagnosis of 
pancreatic cystic neoplasms remains a challenge because available diagnostic techniques are 
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not so specific. The analysis of pancreatic cyst fluids obtained from various cystic lesions 
showed that specific histological lesions are associated with distinct protein patterns. Two 
important factors, olfactomedin-4 (antiapoptotic protein that promotes tumor growth) and 
mucin-18 (melanoma cell adhesion molecule) were proposed as biomarkers of pancreatic 
cancer (Cuoghi et al., 2011). 
CD99 (cell surface glycoprotein involved in leukocyte migration), a useful diagnostic marker 
for Ewing sarcoma/primitive neuroectodermal tumor (Rocchi et al., 2010) was proposed for 
differentiation of solid-pseudopapillary neoplasm from other pancreatic tumor. The tissues 
positivity for CD99 was investigated in a recent study (Guo et al., 2011) using 
immunohistochemical staining technique. The solid-pseudopapillary neoplasm cells tumors 
exhibited paranuclear dot-like immunoreactivity for CD99. In contrast, in pancreatic 
neuroendocrine tumors a small percent of PDAC stained positive for CD99 at cytoplasmatic 
and membrane level. Pancreatic solid-pseudopapillary neoplasm exhibits a unique dot-like 
staining pattern for CD99 and could provide a definitive diagnosis of solid-pseudopapillary 
neoplasm and differentiation from other pancreatic tumors. 
Immunohistochemical analysis of pancreatic cancer tissue provided also several candidate 
biomarkers for survival estimation. CDCP1 (CUB domain containing protein 1) determines 
anchorage- independent growth and migration of cancer cells. A higher expression level of 
this factor is correlated with the overall survival of pancreatic cancer patients (Miyazava et 
al., 2010). L1-CAM (L1-cell adhesion molecule) expression was also correlated with 
perineural invasion of pancreatic cancer cells and poor survival (Ben at al., 2010). Higher 
expression of B7-H3, a co-stimulatory immune molecule, plays a critical role in the T cell-
mediated immune response and presents a positive correlation with pancreatic cancer 
prognosis. 
KOC (K homology domain containing protein) gene encodes a protein that contains several 
KH domains, which are important in RNA binding and are known to be involved in RNA 
synthesis and metabolism. This protein was found to be overexpressed in pancreatic cancer. 
Immunohystochemical analysis showed strong staining for KOC protein in invasive 
pancreatic tissue carcinomas versus normal pancreatic tissue. It was proposed to be a 
molecular marker with a high sensitivity and specificity in discriminating PDAC from 
benign ductal epithelium (Toll et al., 2009). 
3. Genome candidate biomarkers 
Most of the adenocarcinomas develop gradually from precursor lesions PanINs (Pancreatic 
intraepithelial neoplasias). These events are accompanied by genetic modifications. Most 
genetic abnormalities reported in pancreatic cancer are represented by deletions and 
duplications of specific chromosomal loci, mutations/deletions of oncogenes and tumor-
suppresor genes (KRAS, CDKN1A/p16, TP53, MADH4/SMAD4/DPC4 and BRCA2) 
[www.cancer-genetics.org].  
3.1 Gene expression studies and potential factors involved in pancreas oncogenesis 
Quantification of target mRNA gene levels represents a new tool for genome function 
analysis. High-throughput technologies like gene expression profiling using microarray and 
sequencing become important investigation methods for normal physiological and 
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pathological processes. Therefore, studies based on quantification of gene expression levels 
revealed new potential factors involved in pancreas oncogenesis. Using Affymetrix and 
cDNA microarrays, nearly 1,100 molecules have been reported to be overexpressed in 
PanIN and IPMN lesions. A large majority of these molecules showed elevated mRNA 
levels expression in PDAC and in precursor lesions. Molecules such as S100P, MMP7, 
MUC4, FSCN1, and MUC5AC are found to be overexpressed in all type of lesions PanIN, 
IPMN and PDAC (Harsha et al., 2009). 
Badea et al. using microarray study identificated a number of genes whose over-expression 
appears to be inversely correlated with patient survival: keratin 7, laminin gamma 2, 
stratifin, platelet phosphofructokinase, annexin A2, MAP4K4 and OACT2 (MBOAT2), which 
are specifically upregulated in the neoplastic epithelium (Badea et al., 2008).  
The attention was focused especially on the calcium-binding protein- S100P. This protein 
was found to be expressed in pancreatic precursor lesions PanIN 2 or PanIN 3 and in 
pancreatic tumor creating the possibility to use the quantification of its expression level for 
earlier detection (Dowen et al., 2005). Expression levels of S100P mRNA were found to be 
higher in pancreatic juice from patients with pancreatic cancer and IPMN (Ohucida et al., 
2006). On the other hand, three members of S100A family (S100A2, S100A4, and S100A6) 
were found to be associated with poor prognostic. S100A family members were involved in 
cell cycle regulation and cell invasion (Tanase et al., 2010).  
The STAT3 transcription factor was found to be constitutively activated in PDAC. This is an 
important factor in stem cell self-renewal process, cancer cell survival, and inflammation. A 
close correlation between the levels of tyrosine-phosphorylated STAT3 and of the gp130 
receptor was found. An upregulation of the IL6/LIF-gp130 pathway was also showed to be 
involved in STAT3 activation in pancreatic cancer (Corcoran et al., 2011). The same study 
asserts that STAT3 is required for the development of the precursor pancreatic lesions, 
acinar-to-ductal metaplasia (ADM) and PanIN, therefore evaluation of gp130 and phospho-
STAT3 expression may be an effective biomarker.  
3.2 Angiogenesis factors 
With the increasing use of antiangiogenic agents for the treatment of cancers, is necessary 
the identification of candidate biomarkers for evaluation of the response and resistance. Is 
also, important to identify new biomarkers and to eliminate the risk for antiangiogenic 
therapies failure (Duda et al., 2010).  
EGF (Epidermal Growth Factor), VEGF (Vascular Endothelial, Growth Factor) , heparanase, 
thrombospondin, cathepsins were the most important angiogenic factor specific for 
pancreatic cancer involved in cell growth promoting. The overexpression of EGF and his 
receptor EGFR were linked to tumor staging, but no clear data regarding the overall 
survival are available at this moment (Heidemann et al.,2006). 
Another important factor that acts on angiogenesis process is VEGF. His effects in PDAC are 
increased by interaction with MMP-9, a cellular matrix remodeling factor. The therapy 
against both MMP-9 and VEGF in pancreatic cancer resulted in a significant decrease in 
PDAC growth and microvessel density versus a single target treatment (Tanase-Pistol et 
al.,2008). 
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Heparanases are endoglycosidases that cleave the heparan sulfate side chain of heparan 
sulfate proteoglycans (major membrane components) inducing extracellular matrix 
remodelling. On the other hand, heparanase increased growth factor bFGF (fibroblast 
growth factor) release, stimulating the angiogenesis process (Rohloff et al., 2002)  
Thrombospondin (TSP-1) expression level was linked to a good prognostic for PDAC 
development. TSP-1 protein was found abundantly in stroma surrounding tumor cells and 
its expression is inversely correlated with microvessel density(Tobita et al., 2002).  
The role of cathepsins in pancreatic cancer development and progression is still 
controversed. Cathepsin b (CTSB) and cathepsin l CTSL was found to be overexpressd in 
PDAC. A correlation between CTSB expression level and perineural invasion concludes the 
role of cathepsins in local tumor invasion (Niedergethmann et al., 2000).  
3.3 ZIP3 (Zinc/iron regulated transporter-related protein 3) a possible tumor 
suppressor 
Zinc is the most abundant trace element in cells. For example, about 25% of the total zinc 
present is found within the cell nuclei, being a component of chromatin. Zinc is an 
important factor in cellular processes, including cell division and proliferation, immune 
function, and defense against free radicals; zinc deficiency may be associated with an 
increased risk of cancer (Christudoss et al.,2011; Prasad et al., 2002). Zinc is found in over 
300 enzymes, including copper/zinc superoxide dismutase, which is an important 
antioxidant enzyme, involved in cellular protection components from oxidation and 
damage. 
In a current study, Costello et al. found a major loss of zinc in ductal and acinar epithelium in 
adenocarcinoma compared to the normal epithelium (Costello et al., 2011). The decrease in 
zinc quantity is a characteristic not only for pancreatic cancer, but also for precursor lesions. 
The mentioned group showed that the gene expression of ZIP3 (basilar membrane zinc uptake 
transporter) is present in normal ductal/acinar epithelium and absent in adenocarcinoma. The 
decreased expression of ZIP3 determines the loss of zinc in early and progressing malignancy. 
RREB1 transcription factor was found to be down regulated along with ZIP3 and might be the 
silencing cause of ZIP3 gene. Zinc treatment exhibited cytotoxic effect on Panc1 cell line. ZIP3 
and RREB-1 expression level changes represent early events in the development of 
adenocarcinoma suggesting that ZIP3 might be a tumor suppressor gene. 
3.4 Other important factors 
FAP (fibroblast activation protein) is involved in the control of fibroblast growth or 
epithelial-mesenchymal interactions during development, tissue repair, and epithelial 
carcinogenesis. It is highly expressed in PDAC and is considered to be related to a poor 
prognostic. Targeting FAP factors are considered to be a promising and a new 
therapeuthical road (Cohen et al., 2008). 
Maspin (SerpinB5- mammary serine protease inhibitor) is a tumor suppressor gene. Maspin 
induces apoptosis in neoplastic cells and expression of maspin are suppressed as the 
carcinoma progresses in breast and prostatic carcinoma (Jiang et al., 2002). The pattern of 
maspin gene expression is dependent of the disease stage. For example, highly expression 
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was observed in intraductal papillary mucinous neoplasms, mucinous cystic neoplasms. 
and in carcinomas, whereas in adenomas is lower.It was also observed a significant decrease 
in maspin expression when intraductal papillary mucinous neoplasms progresses to 
invasion. However, the group with high maspin expression presented microinvasion, 
whereas low expression maspin group showed extensive invasion (Kashima et al., 2008). 
These results conclude that maspine could be a good prognostic factor for invasion. 
4. Cancer stem cell biomarkers  
Stem cell markers are a promising group of new biomarkers. Solid tumors contain small 
proportions of cells that are capable of proliferation, self-renewal, and differentiation into 
various cell types. These types of cells (cancer stem cells) are characterized by treatment 
resistance, especially to ionizing radiation. Therefore, it is a very challenging situation in 
order to identify these cells, to understand the mechanisms of resistance, and to evaluate the 
patient therapy outcome regarding the response to treatment. Identifying the markers that 
characterize cancer stem cells is the main research and a specific pattern regarding cell 
surface markers is emerging. In breast cancer, stem cells presented a characteristic antigenic 
pattern, whereas in high-grade gliomas, expression of CD133 on the cell surface selects a 
population of treatment resistant cells (Woodward & Sulman, 2008). 
In pancreatic cancer, several surface markers have been identified for a subpopulation of the 
tumor cells with stem cell characteristics. These cancer stem cells were identified by 
expression of the cell surface markers CD44, CD24, and ESA (Li et al., 2007). When injected 
in the pancreas of immunocompromised mice these human cells are able to self-renew and 
generate differentiated progeny, to recapitulate the phenotype of the tumor from which they 
were derived.  
Another subpopulation of cancer stem cells highly tumorigenic was isolated from patients 
with PDAC. These cell types were CD133+ and were able to induce tumor formation in 
athymic mice. This subpopulation of migrating cancer stem cells are characterized also by 
expression of the CXCR4 receptor and are involved in tumor metastasis Hermann et al., 
2007.  
Another candidate cell marker investigated was aldehyde dehydrogenase 1A1 (ALDH1A1), 
which has been identified to label cancer stem cells in breast cancer (Ginestier et al., 2007), 
colon cancer (Huang et al., 2009), lung cancer (Jiang et al., 2009) and head and neck 
squamous cancer (Chen et al., 2009). ALDH1 is a member of the aldehyde dehydrogenase 
gene (ALDH) superfamily playing an important role in the metabolism of endogenous and 
exogenous aldehydes. This NAD(P)(+)-dependent enzyme is also involved in the formation 
of molecules that are important in cellular processes, like retinoic acid (acting like modulator 
of gene regulation and cell differentiation), betaine and gamma-aminobutyric acid and 
exhibits additional, non-enzymatic functions, being able to bind to some hormones (Yoshida 
et al., 1998). The ALDH1 gene expression is ubiquitous in many human tissues; the protein 
is found localized mainly in the cellular cytoplasm.  
It was also shown that ALDH1 has the capacity to detoxify aldophosphamide, conferring 
chemoresistance against cyclophosphamide to overexpressing cell (Hilton, 1984). Data 
regarding the effect of ALDH1A1 overexpression are controversial. Increased expression of 
www.intechopen.com
 Novel Biomarkers in Pancreatic Cancer 
 
37 
ALDH1 in ovarian cancer correlates with a favourable prognostic. In contrast, pancreatic 
cancer increased expression of ALDH1A1 was correlated with poor survival (Rasheed et al., 
2010).  
ALDH1+ breast tumors are negative for estrogen receptor and progesterone receptor 
overexpression, but present a high level of Ki67 expression (a nuclear protein that is 
associated with cellular proliferation) (Morimoto et al., 2009). Therefore, Kahlert et al. 
showed that a high expression of ALDH1A1 is significantly correlated with the proliferation 
rate of pancreatic tumour cells (Kahlert et al., 2011).  
5. Drug-related biomarkers 
Most of the pancreatic cancer patients have inoperable disease due to distant metastases or 
locally advanced tumor and the main therapeutic decision in this case is systemic 
chemotherapy or chemoradiation. Therefore, understanding the mechanisms that govern 
drug-related resistance and the factors involved in this process are a mandatory condition 
for therapeutic management success. 
5.1 Metabolic prognosis factors for gemcitabine resistance 
Patients with advanced or metastatic pancreatic cancer are treated with gemcitabine as a 
first line chemotherapeutic agent. Gemcitabine is a 2′,2′-difluoro-2-deoxycytidine analogue 
that inhibits DNA replication and repair. Gemcitabine possesses radiosensitizing properties 
and its administration must be combined with radiotherapy. The sensitivity to gemcitabine 
and its efficiency were correlated with several factors. One of the factors that correlate with 
gemcitabine sensitivity is hENT1 (human equilibrative nucleoside transporter 1) (Nakano et 
al., 2007).  
Pancreatic cancer cells that highly express hENT1 are sensitive to gemcitabine by uptaking 
this therapeutic agent in cancer cells. The absence hENT1 expression in metastatic pancreatic 
adenocarcinoma pacients treated with gemcitabine was associated with a poor prognostic 
compared with patients whom tumor cancer cells presented hENT1 expression (Hamada & 
Shimosegawa, 2011). 
At the cellular level, gemcitabine is phosphorylated to its active metabolites by dCK 
(deoxycytidine kinase). Another group reported that not only hENT1 higher expression is a 
possible prognostic factor, but also dCK expression level and its activity correlates with 
gemcitabine activity (Ashida et al., 2009). High dCK enzyme activity was linked with 
gemcitabine sensitivity in experimental models (Kroep et al., 2002) and biopsy samples 
analysis (Sebastiani et al., 2006). 
Gemcitabine inactivation is performed through an enzymatic deamination process. There 
are three important enzymes involved in gemcitabine deamination (deoxycytidylate 
deaminase-DCD, cytidine deaminase-CDA and 5'-nucleotidase -5'-NT). The increased 
activity of such enzymes could induce the resistance to gemcitabine (Kroep et al., 2002; 
Giovannetti et al., 2006; Nakano et al., 2007) Gemcitabine resistance mechanism is also 
realized by high expression of RRM1 and RRM2, which are the two subunits (large and 
small) of ribonucleotide reductase. This enzyme regulates the rate of DNA synthesis, and is 
also known to convert ribonucleotides to deoxyribonucleotides. Gemcitabine exerts its 
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cytotoxicity by inhibiting ribonucleotide reductase (Davidson et al., 2004; Bergman et al., 
2005; Nakahira et al., 2006) 
6. Epigenetic biomarkers 
Cancer initiation and progression is traditionally characterized as a genetic alteration, but 
recent years crystallized in a new direction regarding epigenetic mechanisms involvement in 
oncogenesis. Epigenetic mechanisms are essential for normal development and for 
maintaining of a tissue specific pattern of gene expression. Epigenetic modifications lead to an 
abnormal genetic expression and further to malign transformation. The research in epigenetic 
field has demonstrated the involvement of an intensive reprogramming of epigenetic 
machinery (DNA methylation, histone modifications, microRNA expression). The reverse 
nature of epigenetic abnormalities permitted the development of epigenetic therapy field. 
6.1 Gene promoter methylation status and pancreatic oncogenesis 
The most known epigenetic modification in oncogenesis is DNA hypermethylation. This 
event is accompanied by genetic silencing. Identification and characterization of 
epigenetically silenced genes is important in order to understand the roles of such 
epigenetic modification in oncogenesis and to discover new tumor markers. It was reported 
that in pancreas cancer some tumor suppressor genes presented aberrant CpG islands 
hypermethylation at gene promoter level.  
The first tumor suppressor gene identified to be specific for pancreatic cancer was 
p16/CDKN1A (Schutte et al., 1997). Subsequently, new hypermethylated genes were 
associated with pancreatic cancer (hMLH1, E-cadherin, ppENK, CDKN1C, SPARC, TFPI-2, 
GATA4,5, BNIP3, TSLC1, HHIP, MUC2, reprimo, CXCR4 si SOCS1) (Omura et al., 2009).  
Several important epigenetically silenced factors have been identified (hsa-miR-9-1, ZNF415, 
CNTNAP2 si ELOVL4) (Omura et al 2009; Grady et al.,2008; Lehmann et al,.2008; Fabbri et 
al., 2007; Moriss et al., 2004). 
Using methylated CpG island amplification (MCA) and representational difference analysis 
(RDA), Ueki et al group identified that gene preproenkephalin (ppENK) presented a 
hypermethylated promoter in most pancreatic cancers (Ueki et al., 2001). ppENK encodes an 
opioid peptide which presents growth-suppressor properties. 
It was showed that CDKN1C/p57KIP2 gene presented a decrease expression in intraductal 
papillary mucinous neoplasm. The gene encodes for cyclin-dependent kinase inhibitor, and 
is a negative regulator of cell proliferation (Sato et al., 2005). Partial methylation of the 
CDKN1C promoter was found in pancreatic cancer cell lines and pancreas cancer.  
SPARC (secreted protein acidic and rich in cysteine, or osteonectin/BM40) is a matrix-
associated protein; calcium binding, that inhibits cell-cycle progression, and influences the 
synthesis of extracellular matrix. The gene codifying this protein was found aberrantly 
methylated in pancreatic cancer by. SPARC is a factor involved in many processes like cell 
migration, proliferation, matrix cell adhesion (Sato et al., 2003, Gao et al., 2010). 
Tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor, which 
has been identified as a putative tumor-suppressor gene. Aberrant methylation of TFPI-2 
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was found in pancreatic cancer xenografts and primary pancreatic adenocarcinomas. Re-
expression of the TFPI-2 gene led in the proliferation, migration and invasion of cancer cells 
(Sato et al., 2005).  
 GATA gene family members were also epigenetic silenced in pancreatic cancer. For 
example, GATA-5 was frequently methylated in pancreatic cancers, whereas GATA-4 was 
hypomethylated (Fu et al., 2007).  
Another gene commonly silenced epigenetically in pancreatic cancer is BNIP3. The protein 
encoded by this gene contains a BH3 domain and a transmembrane domain associated with 
pro-apoptotic function. BNIP3 gene silencing induced a drug resistance mechanism in 
pancreatic cancer cells, as a potential drug resistance mechanism (Okami et al., 2004)  
Shimizu et al. using a novel method called "microarray coupled with methyl-CpG targeted 
transcriptional activation" (MeTA-array for short), identified 16 genes hypermethylated in 
three representative pancreatic cancer cell lines, AsPC-1, MIA PaCa-2 and PANC-1. Among 
these 16 genes several presented higher methylation level (CSMD2, SLC32A1, TMEM204 
and TRH). CSMD2, SLC32A1 and TRH genes presented also a hypermethylated pattern in 
primary pancreatic cancers (Shimizu et al., 2011).  
In contrast, a great number of genes are overexpressed in pancreatic cancer. These genes 
presented hypomethylation of the promoter in pancreatic cancer versus normal pancreatic 
tissue. 
DNA hypomethylation of promoter CpGs were identified in genes with overexpression 
pattern including claudin4, lipocalin2, 14-3-3sigma/ stratifin, trefoil factor 2, S100A4, 
mesothelin, PSCA, S100P and maspin (Sato et al., 2003). 
6.2 Histone modifications hallmarks for oncogenesis process  
Covalent histone modifications are important regulatory elements in many biological 
processes. These modifications control the chromatin status by electrostatic interaction 
changes and non-histonic protein recruitement. Histones suffer specific N-terminal end 
post-translational changes represented by acethylation, methylation, phosphorylation, 
sumoylation, ubiquitination and ADP-ribosylation. These modifications alter DNA-histones 
interaction having a major impact on chromatin structure (Strahl et al., 2000).  
Certain histone modifications influence gene transcription level. The interplay between 
histone modifications led to ‘histone code hypothesis’. For example, lysine acetylation 
neutralizes the charge between DNA and histone tails and correlates with a more 
transcription permissive status of chromatin (Jenuwein et al., 2001).  
Hypermethylated CpG islands of silenced tumor-suppressor genes are correlated with 
deacetylation of histones H3 and H4, methylation of H3 lysine 9 (H3K9), H3 lysine 27 
(H3K27), and H4 lysine 20 (H4K20), and demethylation of H3 lysine 4 (Rosenfeld et al., 2009; 
Barski et al., 2007). Methylation of histone H3 lysine 4 (H3K4) and H3 lysine 36 is associated 
with relaxed chromatin status (Benevolenskaya et al., 2007). Histone modifications recruit 
effector proteins. Acetylated lysines are recognized by bromodomains within nucleosome 
remodeling complexes, methylated H3K4 and the helicase Chd1 chromodomain recruits 
activating complexes of chromatin (Daniel et al., 2005). In contrast, methylated H3K9 and 
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H3K27 interacts with heterochromatin protein 1 (HP 1) and Polycomb-group (PcG) proteins 
leading to chromatin compaction (Fischle et al., 2003). PcG proteins function as 
transcriptional repressors, but the molecular mechanisms of Polycomb repressive complex 
(PRC)-mediated repression is not clear (Sparmann et al., 2006). PcG proteins recruits 
DNMTs (DNA methyl transferase) involved in the hypermethylation of tumor suppressor 
genes (Vire et al., 2006). 
Only few studies have examined genes that are regulated by histone modifications in 
pancreatic cancers. For example, mucin family gene underwent histone alterations in 
pancreatic cancers in association with gene overexpression. The 5’ region of MUC1 gene 
transcriptional start site is enriched in tri/dimethylated H3K9 and methylated DNA in non-
tumor cells (Yamada et al., 2008). Transcriptional start site of MUC2 is highly enriched in di- 
and tri-methylated H3K4, acetylated H3K9, and acetylated H3K27 in pancreatic cancer cells. 
Vincent et al demonstrated that MUC4 transcription activity is affected by many factors 
(DNMT3A, DNMT3B, HDAC1 and HDAC3, DNA methylation, histone modification 
(Vincent et al., 2008).  
7. Model organisms studies provide potential biomarkers in pancreas 
oncogenesis 
Model organisms are widely used to explore potential causes and treatments for human 
disease. This strategy is made possible by the conservation of metabolic and developmental 
pathways and genetic material over the course of evolution.  
It is known that Enolase 1 (ǂ-enolase or non-neuronal enolase –NNE), is an isoenzyme of 
enolase, which catalyze the conversion of 2-phosphoglycerate into phosphoenolpyruvate. 
Several studies have shown that enolase 1 plays an important role in in tumorigenesis, 
cancer invasion and metastasis. Proteomic studies reported that expression of enolase 1 is 
increased in cancers, such as hepatocellular carcinoma (Takashima et al. 2008, Hamaguchi et 
al., 2008) , non-small lung cancer (He et al., 2007), esophageal adenocarcinoma (Zhao et al., 
2007), prostate cancer (van den Bemd et al., 2006), colon cancer (Katayama et al., 2006), oral 
epithelial and squamous cell carcinoma (Ito et al., 2007).  
In pancreatic cancer Mikuriya et al using two-dimensional electrophoresis and liquid 
chromatography-mass spectrometry/mass spectrometry showed that the expression levels 
of glycolytic enzymes, including enolase 1, increased in the cancerous pancreatic tissues 
patients compared with the paired non-cancerous tissues (Mikuriya et al., 2007). 
In order to evaluate Enolase 1 expression changes, Lei et al. used chemical induced 
carcinogenesis in rats. Implantation of 7,12-dimethylbenzanthracene in rat pancreas leads to 
pancreatic cancer and PanINs. Alpha-enolase was specifically overexpressed in tumors 
compared with normal and pancreatic tissues (Lei et al., 2011).  
The group found several proteins overexpressed in this carcinogenesis model, along with 
enolase 1 (Tumor protein translationally controlled 1, Expressed in non-metastatic cells 2, 
Pancreatic elastase 3B , Necdin, Hbp23, Chromodomain helicase DNA-binding protein, 
Albumin+retinoid X receptor-interacting protein, Heterogeneous nuclear ribonucleoprotein 
A2/B1-hnRNP A2/B1). 
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The hnRNP A2/B1 protein plays an important role in the biogenesis and transport of 
mRNA. Abnormal expression of this protein leads to alteration of normal transcription. In 
concordance with this study a previous work found high levels of hnRNP A2/B1 expression 
in a limited number of human pancreatic adenocarcinomas from smokers and two 
pancreatic tumor cell lines, HPAF-11 and SU 86 (Shen et al., 2004). In contrast, carboxyl ester 
lipase (CEL pancreatic exocrine enzyme) expression level progressively decreased with 
DMBA-induced disease severity.  
DMBA implantation into the rat pancreas is an effective method to induce PanINs and 
pancreas cancer in order to determine which the first change in proteins expression pattern 
is, and to identify markers for pancreas lesions progression. 
8. Novel biomarkers for the non-invasive diagnosis of pancreatic cancer 
Actually, diagnostic methods for pancreatic cancer include invasive procedures (tissue 
sampling by endoscopy), involving risks and causing complications. The necessity for less 
invasive diagnostic methods is increasing; therefore the development of non-invasive 
biomarkers in pancreatic cancer is mandatory. 
8.1 Plasma biomarkers 
The major directions of proteomic range from basic research to discovery, validation and 
use of clinical applications. Protein profiling methods include high resolution two-
dimensional gels, two-dimensional differential in-gel electrophoresis, LC-MS and LC-
MS/MS using accurate mass tags, and protein identifications using mass spectrometry 
methods. These methods were used in many studies for identification of prognostic and/or 
predictive biomarkers that may help stratify patients. 
The only clinically available serum biomarker for PDAC is CA 19-9, which is useful for the 
follow-up of pancreatic cancer patients receiving treatment, but has not been recommended 
for cancer screening (Goggins et al., 2000; Locker et al., 2006). The American Society of 
Clinical Oncology (ASCO) 2006 guidelines for the use of tumor markers do not recommend 
CA19-9 as a screening test for pancreatic cancer (Rosty et al., 2002; Liang et al., 2009). Several 
other serum markers have been proposed for pancreatic cancer. 
Recent papers published new promising biomarkers, which can potentially detect early 
stage pancreatic cancer (Chen et al., 2011). 
Roberts et al. analyzed serum samples from patients with locally advanced or metastatic 
adenocarcinoma of the pancreas. Patient group was selected based on length of survival and 
type of therapy, and serum was subjected to liquid chromatography coupled to tandem mass 
spectrometry analysis (LC-MS-MS) (Roberts et al., 2011). The proteins presenting important 
changes in expression levels were validated by enzyme-linked immunosorbent assay (ELISA). 
After the data were analyzed, the authors selected 1 putative prognostic protein, alpha 1-
antichymotrypsin (AACT), and 2 putative predictive proteins, histidine-rich glycoprotein 
(HRG) and complement factor H (CFH). AACT was found to be negatively correlated with 
overall survival, whereas CFH was found to have no predictive value as prognostic factor for 
overall survival. AACT may be a useful prognostic marker in patients with advanced stage 
pancreatic carcinoma, although additional validation studies are needed. 
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Another study involving quantification in patient serum of tumor cell metabolites, or 
secreted factor was conducted by He et al. . This study focused on DJ-1 oncoprotein secreted 
by cancer cells (He et al., 2011). The study group involved patients diagnosed with 
pancreatic cancer and chronic pancreatitis, along with healthy subjects. DJ-1 serum level and 
the conventional tumor marker carbohydrate antigen 19-9 (CA 19-9) were measured in 
order to establish the diagnostic and prognostic value of DJ-1. Serum DJ-1 level was 
increased in patients with pancreas cancer compared with chronic pancreatitis and healthy 
individuals. Serum DJ-1 levels were higher than CA 19-9, and combined the two biomarkers 
provided a sensitivity of 87.5%. After resection DJ-1 levels decreased and patient with lower 
value of this factor had a better prognosis. This study provides a potential clinical 
biomarker, easy to quantify from serum, in order to establish a rapid diagnosis and to 
evaluate prognosis in patients with pancreas cancer.  
8.2 Pancreatic juice biomarkers 
Analysis of protein expression profiles of pancreatic juice samples harvested from the 
pancreatic duct has the potential to identify markers that could serve for diagnosis triage of 
benign from malignant pancreatic lesions and to discriminate between different stages of 
PDAC. 
The research performed by Vareed et al. has shown that 56 proteins were found to be 
elevated in pancreatic juice of PDAC patients compared to benign controls (Vareed et al., 
2011).  
Protein profiles studies revealed an unique presence of proteins associated with Parkinson’s 
disease namely: aSyn and PARK7 (Bonifati et al., 2003; Singleton et al., 2003).  
Increased expression of aSyn has been also identified in melanoma (Matsuo et al., 2010), 
while its isoform gamma-synuclein (cSyn) has been shown to be elevated in tumors of 
breast, uterine, colorectal and pancreas (Ye et al., 2009; Hibi et al., 2009; Ahmad et al., 2007; 
Li et al., 2004; Gupta et al., 2003; Jia et al., 1999; Morgan et al., 2009). Moreover, due to the 
structural omology between cSyn and aSyn, these factors potentiate invasion in these 
tumors. 
Interestingly, tissue arrays demonstrated a strong staining for aSyn in tumors, and this protein 
expressed in a subset of PDAC patients was identified in its aggregated form similar to Lewy 
Bodies seen in Parkinson’s disease (Polymeropoulus et al., 1997). Another interesting 
coincidence is the presence of increased levels of Parkinson’s disease associated protein 
PARK7 (DJ1) (van Duijin et al., 2001) in pancreatic ductal juice of adenocarcinomas. The 
mechanism by which the protein PARK-7 exerts its oncogenic effect remains unclear. It is 
presumed the involvement of p38 mitogen activated-protein kinase signaling (Mo et al., 2010).  
On the other hand PDAC-associated secretory proteome analysis also revealed increased 
levels of several metabolic enzymes. The most important metabolic factor was Purine 
NucleosidePhosphorylase (NP), enzyme involved in salvage pathway of purines, which is 
operational during inflammation and neoplastic progression, (Bantia et al., 2010). NP 
activity has been reported to be high in cancer sera (Roberts et al., 2004) and NP expression 
has also been used to determine the clinical severity of various types of cancers, in 
combination with another factor adenosine deaminase (ADA) (Mesarosova et al., 1993).  
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This strong association between NP with inflammation determined to evaluate the 
expression and activity of this protein in PDAC, specifically in patients with antecedent 
inflammatory conditions like chronic pancreatitis, and pancreatic intraepithelial neoplasia 
(PanIN) (Rebours et al., 2010). Therefore, this correlation makes NP levels quantification to 
be a useful marker for surveillance progression from inflammation to PDAC. 
8.3 Saliva biomarkers 
Saliva is a body fluid that can be easily obtained without using a special technique. Recent 
reports suggested the possible utility of saliva in quantification of specific factors to 
discriminate between pancreatic cancer patients and patients with normal or chronic 
pancreatitis. 
Using transcriptome profiles, Zhang et al. group could differentiate pancreatic cancer 
patients from healthy subject with a sensitivity of 90.0% and a specificity of 95.0%. The 
group found 12 mRNA biomarkers specific for pancreatic cancer patients. Seven genes were 
found to be up-regulated (MBD3L2, KRAS, STIM2, DMXL2ACRV1, DMD, CABLES1), 
whereas five genes presented a decreased expression TK2, GLTSCR2, CDKL3, DPM1, TPT1 
(Zhang et al., 2010). 
A similar approach has been made by another group, which evaluated metabolites in saliva 
using mass spectrometry. Pancreatic cancer cases were successfully detected based on the 
pancreatic cancer-specific signature (Sugimoto et al., 2010). The levels of ornithine and 
putrescine were higher in patients with breast or pancreatic cancer, and were markedly 
higher in patients with oral cancer. The level of tryptophan is also increased in oral and 
pancreatic cancer, in contrast to arginine level which is decreased several cancers including 
breast, colonic and pancreatic cancer, which might be due to increased uptake of arginine by 
tumor tissues with high arginase activity. 
8.4 Non- coding RNA as new era biomarkers 
A new and important atractive tool is represented by small non-coding RNA. These are 
regulators of various biological processes like gene expression and are involved in cancer 
progression. One of the most important players is microRNAs which control many cellular 
functions, such as migration, invasion and stem cell functions. Abnormal microRNA gene 
expression was found in many cancers, including pancreatic cancer (Rachangani et al., 2010, 
Eis et al., 2005, Calin et al., 2005, Yanaihara et al., 2006).  
MicroRNA molecules are present in various body fluids (blood, urine, cerebrospinal fluid, 
pancreatic juice, billiary secretion). Moreover, several microRNAs from sera seemed to be 
identical for many cancer types. Very important is the fact that miRNAs from sera are stable 
and exhibit resistance to RN-ase activity, intermittent frosting and defrosting, high 
temperature values and extreme pH ( Mitchell et al., 2008; Albulescu et al., 2011). 
Using microarray technology it was established that several microRNAs are highly 
expressed in pancreatic cancer (miR-21, miR-17-5p,miR-191,miR-29b-2,miR-223 miR-128b, 
miR-199a-1, miR-24-1, miR-24-2,miR-146, miR-181b-1, miR-20a,miR-107,miR-32 , miR-92-2, 
miR-214,miR-30c, miR-25, miR-221, miR-106) (Volinia et al., 2006). More recently, was 
established that microRNAs, miR-200a and miR-200b are highly expressed in pancreatic 
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cancer cell lines, and their expression levels were significantly increased in the sera from 
pancreatic cancer patients, suggesting that microRNA itself could be a biomarker for 
pancreatic cancer (Li et al., 2010). The attention was also focused on two pancreas specific 
miRNAs miR-216 and miR-217. The expression of those miRNAs is decreased or even 
absent in PADC and in cell lines (Sood et al., 2006). Only miR-217 and miR-196a are able to 
discriminate between normal pancreas, chronic pancreatitis and tumor PDAC (Szafranska et 
al., 2008). Furthermore, miR-196a expression is likely specific to PDAC cells and is positively 
associated with the progression of PDAC.  
miR-21 and miR-155 are overexpressed in pancreatic tumor, as compared to tissues from 
normal pancreas and chronic pancreatitis. Both miR-21 and miR-155 have been suggested to 
have a proto-oncogene role being overexpressed in several cancers (breast cancer, lung 
cancer, Burkitt lymphoma, B-cell lymphoma) (Metzler et al., 2004;Yin et al., 2008)  
Several studies demonstrated that miR-155 transcription is regulated by transforming 
growthfactor ǃ -TGF ǃ/Smad, nuclear factor-κB and activator protein-1 family transcription 
factors through direct interaction with the miR-155/BIC bidirectional promoter. These  
studies suggests that overexpression of miR-155 in cancer is due to transcriptional 
activation, involving other cellular deregulated mechanisms (Kong et al., 2008). 
9. Conclusions 
Asymptomatic pancreatic cancer is hard to detect, but possibly curable. Recent research 
identified novel biomarkers of pancreatic cancer, but screening for early pancreatic cancer is 
still challenging. Future work should be addressed to the development of diagnostic 
techniques with a higher sensitivity to detect even asymptomatic cases. Currently no 
clinically useful interventions to screen for patients with PDAC are available.  
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